OrthoPediatrics Corp. (KIDS) SEC Filings & Earnings Calls

Activist holder reducing stake

“On September 10, 2026, SC LLC sold 302,369 shares of Common Stock for a weighted average price of $21.01. These sales were undertaken by SC LLC to provide additional capital for its other portfolio businesses.” · word for word

Major shareholder selling for portfolio rebalancing

“These sales were undertaken by SC LLC to provide additional capital for its other portfolio businesses.” · word for word

Major shareholder selling for portfolio rebalancing

“These sales were undertaken by SC LLC to provide additional capital for its other portfolio businesses.” · word for word

Persistent operating losses and accumulated deficit

“As of June 30, 2026, we had an accumulated deficit of $293.1 million.” · word for word

Scoliosis segment decline

“Scoliosis sales decreased $1.6 million, or 9%, from $18.5 million during the three months ended June 30, 2025, to $16.9 million for the three months ended June 30, 2026.” · word for word

Foreign exchange exposure

“We incurred a foreign exchange transaction loss for the six months ended June 30, 2026 driven largely by the strengthening of the US Dollar against the Euro.” · word for word

Scoliosis revenue decline of 9% due to lower 7D Technology and international set sales

“Scoliosis revenue was $16.9 million, a 9% decrease compared to $18.5 million for the second quarter of 2025. The decrease was due to decreased revenue generated from 7D Technology as well as lower set sales to our international stocking distributors” · word for word

Net loss remains elevated at $7.2M, similar to prior year

“Net loss for the second quarter of 2026 was $7.2 million, compared to $7.1 million for the same period last year” · word for word

Cash and investments decreased $15M from prior year end

“As of June 30, 2026, cash, cash equivalents, short-term investments and restricted cash were $47.9 million compared to $62.9 million” · word for word

Accumulated deficit and ongoing losses

“We have incurred operating losses since inception which resulted in negative cash flows used in operating activities of $3.3 million and $4.2 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we had an accumulated deficit of $285.9 million.” · word for word

High leverage and debt covenants

“Included in the term loan are financial covenants to maintain cash in certain pledged accounts of at least 25% of the outstanding principal amount of the loan and to maintain certain minimum net product sales during the loan period.” · word for word

Foreign exchange loss impacted other income

“decrease in foreign exchange gain”

Equity dilution from increased share authorization

“the Board approved, subject to and contingent on stockholder approval at the annual meeting, an amendment to the 2024 Plan to increase the number of shares authorized under the 2024 Plan by 2,050,000 shares” · word for word

Increased debt capacity but with high interest cost (SOFR+6.5%) and fees.

“Interest at a rate per annum equal to the SOFR Interest Rate (with a floor of 3.25%) plus 6.50%... 1.00% upfront fee, a 0.05% per annum delayed draw ticking fee.” · word for word

Sustained Operating Losses

“We had operating losses of $39.2 million, $35.0 million and $26.8 million for the years ended December 31, 2025, 2024 and 2023, respectively.” · word for word

Medicaid Reimbursement Risk

“Legislative or regulatory changes at the federal or state level that reduce Medicaid enrollment, restrict coverage for specific procedures or devices, or lower reimbursement rates could negatively impact our business.” · word for word

Tariff Cost Risk

“Tariffs and potential retaliation could significantly increase the cost of our products and reduce demand.” · word for word

Net loss persists despite improvement; operating expenses increased $3.7M in Q4.

“Net loss for Q4 2025 was $10.1 million; total operating expenses increased $3.7 million”

Preliminary unaudited results subject to audit adjustment; guidance dependent on execution.

“The financial information set forth in this Form 8-K reflects the Company's current preliminary net revenue and free cash flow estimates, is subject to the completion of its audit process, and is subject to change.” · word for word

Continued operating losses and negative cash flows

“We have incurred operating losses since inception which resulted in negative cash flows used in operating activities of $15.2 million and $23.1 million for the nine months ended September 30, 2025 and 2024, respectively.” · word for word

Intangible asset impairment and restructuring

“We recorded an impairment charge of $2.3 million for the nine months ended September 30, 2025 compared to $0 for the nine months ended September 30, 2024.” · word for word

High debt and interest expense

“The interest rate on the term loan is SOFR + 6.50% with the Company having the option to make a payment-in-kind interest payment equal to 1.00% per annum of the rate.” · word for word

Restructuring charges and intangible asset impairment totaling $4.6M

“Restructuring charges $2.3 million, intangible asset impairment $2.3 million”

7D capital sales and Latin/South America underperformed expectations

“7D and Latin and South America did not meet our expectations” · word for word

Free cash flow still negative at -$3.4M

“Free cash flow usage in the third quarter of 2025 was $3.4 million” · word for word